一分钟看懂
这是一项关于非小细胞肺癌的III 期研究，登记的药物或干预包括Lazertinib；Amivantamab；Pemetrexed；Carboplatin，当前状态为研究进行中，已停止招募。登记地点显示中国北京、长沙、成都、重庆等城市有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
Lazertinib；Amivantamab；Pemetrexed；Carboplatin · III 期
登记条件中文摘要
登记的基本范围为不限性别，年龄18 岁；另列出7项专业入选条件，需结合英文原文并由研究团队确认。
登记记录列出6项主要排除条件，具体医学含义需结合英文原文并由研究团队确认。
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- Cancer Hospital, Chinese Academy of Medical Sciences · 北京
- Peking University People's Hospital · 北京
- Beijing Cancer Hospital Chest Tumor Internal Medicine dept. II · 北京
- Beijing Cancer Hospital · 北京
- Chinese PLA General Hospital · 北京
- Beijing Chest hospital, Capital medical university · 北京
- Hunan Cancer hospital 1 · 长沙
- Hunan Cancer hospital · 长沙
- Sichuan Cancer Hospital · 成都
- West China Hospital Sichuan University · 成都
- Chongqing University Cancer Hospital · 重庆
- Southwest Hospital · 重庆
- Daping Hospital Army Characteristic Medical Center · 重庆
- The First Affiliated Hospital Sun Yat sen University · 广州
- Sun Yat-Sen Memorial Hospital Sun Yat-sen University · 广州
- Second Affiliated Hospital, School of Medicine, Zhejiang University · 杭州
- The Second Affiliated Hospital of Zhejiang University College of Medicine · 杭州
- Sir Run Run Shaw Hospital Zhejiang University School of Medicine · 杭州
- Zhejiang Cancer Hospital · 杭州
- Harbin medical university cancer hospital · 哈尔滨
- Huizhou Municipal Central Hospital · 惠州
- Taizhou Hospital of Zhejiang Province · 临海
- Affiliated Hospital of North Sichuan Medical College · 南充
- Ruijin Hospital Shanghai Jiao Tong University · 上海
- Fudan University Shanghai Cancer Center · 上海
- Shanghai East Hospital · 上海
- Shenzhen university General Hospital · 深圳
- Cancer Hospital Chinese Academy of Medical Sciences · 深圳
- Tianjin Medical University General Hospital · 天津
- Weifang People's Hospital · 潍坊
- The First Affiliated Hospital of Xian Jiaotong University · 西安
- Yantai Yuhuangding Hospital · 烟台
- Henan Cancer Hospital · 郑州
公开的入选条件
- * Participant must have at least 1 measurable lesion, according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1, that has not been previously irradiated
- * Participant must have histologically or cytologically confirmed, locally advanced or metastatic, non-squamous non-small cell lung cancer (NSCLC), characterized at or after the time of locally advanced or metastatic disease diagnosis by either epidermal growt
- * A participant with a history of brain metastases must have had all lesions treated as clinically indicated (that is, no current indication for further definitive local therapy). Any definitive local therapy to brain metastases must have been completed at lea
- * Participant must have Eastern Cooperative Oncology Group (ECOG) status of 0 or 1
- * Any toxicities from prior systemic anticancer therapy must have resolved to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 5.0 Grade 1 or baseline level (except for alopecia \[any grade\], Grade \<= 2 peripheral
- * A participant of childbearing potential must have a negative serum pregnancy test at screening and within 72 hours of the first dose of study treatment and must agree to further serum or urine pregnancy tests during the study
- * Participant must have progressed on or after osimertinib monotherapy as the most recent line of treatment. Osimertinib must have been administered as either the first-line treatment for locally advanced or metastatic disease or in the second- line setting af
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT04988295；登记信息更新于 2026-09-21。